Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, July 2001, p. 2163-2168, Vol. 45, No. 7
Infectious Diseases Research, Abbott
Laboratories, Abbott Park, Illinois 60064-3537
Received 5 September 2000/Returned for modification 13 February
2001/Accepted 30 March 2001
The in vitro activities of ABT-773, erythromycin, clarithromycin,
and azithromycin were compared. ABT-773 was the most active compound
against macrolide-susceptible Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Enterococcus
spp. and multidrug-resistant Streptococcus pneumoniae. It
also had good activity against gram-negative and atypical respiratory
tract pathogens and Helicobacter pylori.
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.7.2163-2168.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Comparative In Vitro Activity of ABT-773, a Novel
Antibacterial Ketolide
and
*
Corresponding author. Mailing address: D47T, AP52,
Abbott Laboratories, Abbott Park, IL 60064-3537. Phone: (847) 937-7706. Fax: (847) 935-0400. E-mail: angela.nilius{at}abbott.com.
Present address: Enanta Pharmaceuticals, Cambridge, MA 02139.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |